We are live on ! Find out more
TMBR

Timber Pharmaceuticals, Inc.

Delisted

TMBR was delisted on the 28th of November, 2023.

12 hedge funds and large institutions have $149K invested in Timber Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 1412 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

72% less capital invested

Capital invested by funds: $540K → $149K (-$391K)

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
5
Closed
5
Calls
Puts
Net Calls
Net Calls Change

TMBR Hedge Fund Activity: Q3 2019 in Review

12 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q3 2019, worth a combined $149K — down 72% from $540K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of TMBR and 3 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was Franklin Resources, adding an estimated $1.67M. The largest seller was Vivo Capital, exiting entirely with an estimated $189K sold.

  • 12 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q3 2019, down from 14 in Q2 2019.
  • Funds reported $149K of Timber Pharmaceuticals, Inc. stock for Q3 2019, down 72% quarter-over-quarter.
  • 3 funds opened new Timber Pharmaceuticals, Inc. positions in Q3 2019 and 5 closed out, a net change of -2 holders.
  • The largest Timber Pharmaceuticals, Inc. buyer in Q3 2019 was Franklin Resources, an estimated $1.67M added.
  • The largest Timber Pharmaceuticals, Inc. seller in Q3 2019 was Vivo Capital, an estimated $189K sold.

Based on aggregated 13F filings for Q3 2019.